Get an inside look at the lessons, insights, and opportunities from Ralf Schmid’s visit, including more information about an upcoming partner conference with CureSHANK and Asia-Pacific organizations dedicated entirely to PMS.

Current biomarker assessment tools for neurodevelopmental diseases like PMS can be imprecise and subject to bias, making it harder to objectively measure a treatment's impact. CureSHANK is actively working with expects to evaluate promising biomarker approaches that will provide more accurate and objective measurements for PMS research.